NMPA 30-Working-Day IND Pathway

What Is China's 30-Working-Day IND Pathway?

An investigational new drug application asks regulators for permission to begin or expand clinical testing; it is not a marketing authorization and does not establish that a medicine is safe or effective. The new pathway targets a decision within 30 working days for qualifying applications, compared with the 60-working-day review framework commonly associated with China's clinical trial authorization system.

The shorter timetable is most relevant to developers that can submit mature chemistry, manufacturing and controls information alongside nonclinical pharmacology, toxicology and clinical protocols. Regulators may still request additional information, restrict a protocol or prevent a study from proceeding when unresolved risks outweigh the proposed scientific value.

How Can Sponsors Design a China-Ready Clinical Trial?

A China-ready program begins before the application is filed. Dose selection should be supported by pharmacology and toxicology, while the protocol should define stopping rules, adverse-event reporting, dose-escalation governance and access to emergency care. The investigational product must also be supported by validated manufacturing and quality controls that maintain consistency across study locations.

For multinational studies, the International Council for Harmonisation's E17 guideline recommends advance planning for regional enrollment, clinically meaningful population differences and consistent trial conduct. Early assessment of factors such as body size, genetics, diet, medical practice and background therapy can help determine whether Chinese participants can enter a global protocol directly or whether additional pharmacokinetic evidence is needed.

Will Faster IND Review Bring New Treatments to Patients Sooner?

A shorter review clock can reduce one administrative interval and make it easier to include Chinese research centers earlier in global development. Earlier participation may improve the evidence available for populations that could eventually use the treatment and may reduce the need for separate, duplicative studies.

However, regulatory speed should not be confused with therapeutic success. Most experimental medicines must pass several clinical phases, and unexpected toxicity, inadequate efficacy, poor recruitment or manufacturing problems can delay or end a program. Good Clinical Practice remains essential: informed consent, independent ethics review, reliable data collection and prompt safety reporting must be maintained regardless of the review timetable.